CareLit Fachartikel
T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial
E. Michael Lewiecki, Peter R. Ebeling, E Hesse, N Napoli, Daria B. Crittenden, M Rojeski, W Yang, C Libanati, S Ferrari · Osteologie · 2020 · Heft 01
Dokument
1214316
CareLit-ID
Jahr
2020
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial
Schlagworte
Alendronate
Osteologie